血液循环 miRNA 作为阿尔茨海默病的生物标志物：系统评价和荟萃分析。
Blood circulating miRNAs as biomarkers of Alzheimer's disease: a systematic review and meta-analysis.
机构信息
The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science & Technology, Luoyang 471003, PR China.
出版信息
Biomark Med. 2019 Aug;13(12):1045-1054. doi: 10.2217/bmm-2018-0341. Epub 2019 Aug 6.
It is already known that miRNAs can be differentially expressed in Alzheimer's disease (AD). We aimed to evaluate the performance of miRNAs from blood as potential biomarkers for AD. : MEDLINE, PubMed and Embase were searched for studies about peripheral blood miRNAs that could discriminate patients with AD from cognitively normal controls. The data regarding the specificity and sensitivity were extracted. STATA 14.0 was used to analyze the data. Ten studies containing 770 AD and 664 normal controls. The analysis showed that miRNAs presented excellent diagnostic performance and the overall sensitivity was 0.80 (95% CI: 0.75-0.83), specificity was 0.83 (95% CI: 0.78-0.87) and diagnostic odds ratio was 14 (95% CI: 11-19). Subgroup analysis suggested that the Caucasian group and blood group showed a better performance in AD diagnosis and the diagnostic odds ratio was 42 and 34, respectively. This meta-analysis showed that miRNAs may be a promising biomarkers for AD.
已有研究表明，miRNAs 在阿尔茨海默病（AD）中存在差异表达。我们旨在评估血液中的 miRNAs 作为 AD 潜在生物标志物的性能。：我们检索了 MEDLINE、PubMed 和 Embase 中的研究，以评估外周血 miRNAs 是否可以区分 AD 患者和认知正常对照者。提取了有关特异性和敏感性的数据。使用 STATA 14.0 对数据进行分析。包含 770 例 AD 和 664 例正常对照的 10 项研究。分析表明，miRNAs 具有出色的诊断性能，总敏感性为 0.80（95%CI：0.75-0.83），特异性为 0.83（95%CI：0.78-0.87），诊断比值比为 14（95%CI：11-19）。亚组分析表明，白种人群组和血群组在 AD 诊断中表现出更好的性能，诊断比值比分别为 42 和 34。这项荟萃分析表明，miRNAs 可能是 AD 有前途的生物标志物。
Zotero 插件